Immunocore Holdings plc (IMCR)
Nasdaq · Healthcare · Biotechnology
$29.59−0.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.5B
- 52-week range
- $27.56 – $40.72
- 52-week change
- −13.18%
- EPS (trailing)
- −$0.36
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $400M (+28.96%)
- Net income
- −$35.5M
- Operating margin
- −11.3%
- Diluted EPS
- −$0.71
- Free cash flow
- −$15.1M
From the company’s annual report on SEC EDGAR.
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus.
Headquarters: Abingdon, United Kingdom · 524 employees · immunocore.com